List of Excipients in Branded Drug MUCUS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
walgreens	MUCUS	guaifenesin	0363-0071	CARBOMER HOMOPOLYMER TYPE B
walgreens	MUCUS	guaifenesin	0363-0071	CELLULOSE, MICROCRYSTALLINE
walgreens	MUCUS	guaifenesin	0363-0071	HYPROMELLOSE
walgreens	MUCUS	guaifenesin	0363-0071	MAGNESIUM STEARATE

Generic Drugs Containing MUCUS

Company	Ingredient	NDC	Excipient
CVS Pharmacy	guaifenesin	69842-806	CARBOMER HOMOPOLYMER TYPE B
CVS Pharmacy	guaifenesin	69842-806	CELLULOSE, MICROCRYSTALLINE
CVS Pharmacy	guaifenesin	69842-806	FD&C BLUE NO. 1
CVS Pharmacy	guaifenesin	69842-806	HYPROMELLOSE

What are the Most Frequently-Used Excipients in MUCUS?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE B
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 1
1	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for MUCUS-Based Pharmaceutical Drugs

Last updated: February 28, 2026

What are the primary functions of excipients in mucus-based drugs?

Excipients provide stability, enhance bioavailability, control release, and improve physicochemical properties. In mucus-targeted formulations, excipients stabilize mucus interactions, modulate viscosity, and optimize drug-mucus penetration.

How do excipients influence the formulation of mucus-targeted drugs?

Excipients in mucus drugs are selected to:

• Increase mucoadhesion (e.g., carbomers, chitosan)
• Modulate mucus viscosity (e.g., polyethylene glycol)
• Facilitate drug release and diffusion through mucus (e.g., surfactants)
• Protect active compounds from degradation (e.g., antioxidants)

What are common excipients used in mucus drugs?

Excipients	Function	Examples
Mucoadhesives	Enhance adhesion to mucus layer	Carbomers, chitosan
Viscosity modifiers	Adjust mucus viscosity to optimize residence time	Polyethylene glycol, HPMC
Surfactants	Improve drug solubility and penetration	Polysorbates, bile salts
Stabilizers	Prevent degradation of active compound	Antioxidants (ascorbic acid)
Penetration enhancers	Facilitate drug crossing mucus barrier	Ethanol, bile salts

What are key considerations in developing excipient strategies for mucus drugs?

• Biocompatibility and safety (most excipients are Generally Recognized As Safe - GRAS)
• Compatibility with the active drug
• Effect on mucus clearance and turnover
• Compatibility with delivery route (nasal, oral, pulmonary)
• Regulatory restrictions and approval pathways

What commercial opportunities exist with mucus-targeted excipients?

Market Overview

The mucus drug delivery market is expanding, driven by respiratory, gastrointestinal, and topical applications. The global mucus-targeted drug delivery market was valued at USD 3.2 billion in 2021 and is projected to reach USD 7.1 billion by 2028, growing at a CAGR of 11.2%[1].

Potential for Innovative Excipients

1. Mucoadhesive polymers: Patentable formulations using novel chitosan derivatives or synthetic mucoadhesives can command premium pricing.
2. Bioerodible viscosity enhancers: Development of thin, biodegradable polymers that extend residence time with minimal toxicity.
3. Permeation enhancers: Specialty excipients that temporarily open tight junctions for enhanced drug absorption.

Market Entry Strategies

• Collaborate with excipient manufacturers to develop branded, patent-protected formulations.
• License novel mucoadhesive or penetration-enhancing excipients.
• Focus on niche therapeutic areas with high unmet needs such as cystic fibrosis, ulcerative colitis, or nasal vaccines.

What are the regulatory considerations?

Most excipients used in mucus formulations follow existing monographs (e.g., USP, EP). However, novel excipients or new applications require comprehensive safety data and may need Investigational New Drug (IND) or equivalent filings depending on jurisdiction.

Patent Landscape

Patents in this area cover specific mucoadhesive polymers, novel delivery systems, and combination formulations. Patent filings peaked between 2018-2022 with notable companies such as BioDelivery Sciences and Glenmark Pharmaceuticals leading innovation[2].

Competitive Landscape

Leading players include BioDelivery Sciences, GlaxoSmithKline, and Medgene Labs, focusing on nasal and pulmonary delivery platforms. Smaller biotech firms explore specialized excipients for targeted delivery.

Strategic Opportunities

• Developing proprietary excipient blends to improve drug retention and absorption.
• Creating tailored formulations for respiratory diseases (e.g., COVID-19, COPD).
• Leveraging the potential for over-the-counter (OTC) mucus formulations for allergy relief and cold remedies.

Key Takeaways

• Excipient selection in mucus drugs focuses on mucoadhesion, viscosity control, and permeability.
• Market growth driven by respiratory, gastrointestinal, and topical applications.
• Patent and regulatory pathways favor innovation in mucoadhesive polymers and penetration enhancers.
• Opportunities exist in licensing, formulation development, and niche therapeutic areas.

FAQs

Q1: What makes an excipient suitable for mucus formulations?
Suitable excipients are biocompatible, enhance mucoadhesion, control viscosity, and do not impede drug release or absorption.

Q2: How does mucus viscosity impact drug delivery?
Increased viscosity prolongs residence time but can hinder drug diffusion. Excipients balance these effects to optimize delivery.

Q3: Are there safety concerns with novel excipients in mucus drugs?
Yes. They require extensive safety evaluation, especially if used for prolonged or repeated administration.

Q4: What delivery routes benefit most from mucus-targeted excipients?
Nasal, pulmonary, and oral routes see significant benefits; topical applications for mucosal tissues also leverage these excipients.

Q5: What therapeutic areas offer high growth potential for mucus formulations?
Respiratory conditions, gastrointestinal inflammatory diseases, and vaccines targeting mucosal immunity offer high growth potential.

---

References

[1] Grand View Research. (2022). Mucus-targeted drug delivery market size, share, and trends.
[2] Patent databases and recent patent analyses on mucoadhesive excipients and delivery systems.